{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:22:03Z","timestamp":1762867323407,"version":"3.37.3"},"reference-count":18,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2018,3,31]],"date-time":"2018-03-31T00:00:00Z","timestamp":1522454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2018,8]]},"abstract":"Abstract<\/jats:title>Background & Aims<\/jats:title>Limited data have shown high efficacy of co\u2010formulated ombitasvir\/paritaprevir\/ritonavir (OBV<\/jats:styled-content>\/PTV<\/jats:styled-content>\/r) in the treatment of hepatitis C virus (HCV<\/jats:styled-content>) genotype (GT<\/jats:styled-content>)\u20104, and combined with dasabuvir (DSV<\/jats:styled-content>) in GT<\/jats:styled-content>1 patients, with chronic kidney disease (CKD<\/jats:styled-content>) stages 4\u20105 (<30\u00a0mL\/min\/1.73\u00a0m2<\/jats:sup>). We assessed real\u2010world safety and efficacy of OBV<\/jats:styled-content>\/PTV<\/jats:styled-content>\/r\u00a0\u00b1\u00a0DSV<\/jats:styled-content> in GT<\/jats:styled-content>1\u2010 and 4\u2010infected patients.<\/jats:p><\/jats:sec>Methods<\/jats:title>In this observational cohort (n\u00a0=\u00a067), we enrolled stages 4\u20105 CKD<\/jats:styled-content> treatment\u2010na\u00efve or Peginterferon\/RBV<\/jats:styled-content>\u2010experienced\u00a0GT<\/jats:styled-content>4\u2010infected patients (n\u00a0=\u00a032) treated for 12\u201024 weeks with OBV<\/jats:styled-content>\/PTV<\/jats:styled-content>\/r\u00a0\u00b1\u00a0RBV<\/jats:styled-content>, and plus DSV<\/jats:styled-content> in GT<\/jats:styled-content>1 patients (n\u00a0=\u00a035, including 3 with GT<\/jats:styled-content>1\/4 co\u2010infection). RBV<\/jats:styled-content> was dosed by physician discretion between 200 mg weekly and 200 mg daily. Primary endpoints were SVR<\/jats:styled-content>12, calculated on intention\u2010to\u2010treat (ITT<\/jats:styled-content>) basis, and occurrence of serious adverse events.<\/jats:p><\/jats:sec>Results<\/jats:title>The mean age of the cohort was 45.7\u00a0\u00b1\u00a012.7\u00a0years, 50.7% were females, 20.9% had cirrhosis, 35.8% were treatment\u2010experienced and 97% were on haemodialysis. Three patients (F4) received 24\u2010week treatment, 2 with GT<\/jats:styled-content>4, and 1 with GT<\/jats:styled-content>1a; and 19.4% were treated without RBV<\/jats:styled-content>, including 9 GT<\/jats:styled-content>1, and 4 GT<\/jats:styled-content>4. Overall, 65 (97.1%) patients achieved SVR<\/jats:styled-content>12, including 100% of those with a post\u2010treatment follow\u2010up (modified ITT<\/jats:styled-content> analysis). Of the two patients without SVR<\/jats:styled-content>12, one died from sepsis\u2010related complications and the other from a myocardial infarction 2\u00a0weeks after completing therapy. Grades 3\u20104 anaemia occurred in 8.9%.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>A 12\u2010week regimen of OBV<\/jats:styled-content>\/PTV<\/jats:styled-content>\/r\u00a0\u00b1\u00a0DSV<\/jats:styled-content> with or without RBV<\/jats:styled-content> is highly effective with a favourable safety profile amongst GT<\/jats:styled-content>4 and GT<\/jats:styled-content>1 patients with CKD<\/jats:styled-content> stages 4\u20105. SVR<\/jats:styled-content>12 rates were high regardless of patient characteristics.<\/jats:p><\/jats:sec>","DOI":"10.1111\/liv.13674","type":"journal-article","created":{"date-parts":[[2017,12,30]],"date-time":"2017-12-30T03:56:41Z","timestamp":1514606201000},"page":"1395-1401","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["High Efficacy of ombitasvir\/paritaprevir\/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1\u2013infected patients with severe chronic kidney disease"],"prefix":"10.1111","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3830-9236","authenticated-orcid":false,"given":"Faisal M.","family":"Sanai","sequence":"first","affiliation":[{"name":"Gastroenterology Unit Department of Medicine King Abdulaziz Medical City Jeddah Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah S.","family":"Alghamdi","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit Department of Medicine King Fahad Hospital Jeddah Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad A.","family":"Afghani","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit Department of Medicine King Fahad Hospital Madinah Almunawarrah Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Alswat","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit Department of Medicine & Liver Disease Research Center College of Medicine King Saud University Riyadh Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adnan","family":"AlZanbagi","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit Department of Medicine King Abdallah Medical City Makkah Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mosfer N.","family":"Alghamdi","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit Department of Medicine AlHada Armed Forces Hospital Taif Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdallah","family":"AlMousa","sequence":"additional","affiliation":[{"name":"Hepatology Department King Fahad Specialist Hospital Buraidah Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Aseeri","sequence":"additional","affiliation":[{"name":"Pharmacy Department King Abdulaziz Medical City Jeddah Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah M.","family":"Assiri","sequence":"additional","affiliation":[{"name":"Infectious Disease Department King Fahd Medical City Riyadh Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed A.","family":"Babatin","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit Department of Medicine King Fahad Hospital Jeddah Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,3,31]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26141"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30181-9"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.4103\/1319-3767.188067"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(12)80930-9"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-112-12-958"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0100790"},{"key":"e_1_2_9_8_1","unstructured":"Saudi Center for Organ Transplant Annual Report 2015. Available atwww.scot.gov.sa. Accessed March 4 2017."},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12422"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.02.078"},{"key":"e_1_2_9_11_1","first-page":"470A","article-title":"RUBY\u2010II: efficacy and safety of a ribavirin\u2010free ombitasvir\/paritaprevir\/ritonavir \u00b1 dasabuvir regimen in patients with severe renal impairment or end\u2010stage renal disease and HCV genotypes 1a or 4 infection","volume":"64","author":"Gane EJ","year":"2016","journal-title":"Hepatology"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12664"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60159-3"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402338"},{"key":"e_1_2_9_15_1","first-page":"576A","article-title":"Real\u2010World safety and efficacy of ribavirin\u2013free regimen of ombitasvir\/paritaprevir\/ritonavir for dialysis patients infected with HCV","volume":"65","author":"Derbala M","year":"2017","journal-title":"Hepatology"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00349-9"},{"key":"e_1_2_9_17_1","first-page":"582A","article-title":"Real\u2010world efficacy and safety of Elbasvir and Grazoprevir in HCV genotype 1 or 4 infected patients with severe chronic kidney disease stage 4\/5 or hemodialyzed","volume":"65","author":"Alric L","year":"2017","journal-title":"Hepatology"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704053"},{"key":"e_1_2_9_19_1","unstructured":"KDIGO 2017 Clinical Practice Guideline on the Prevention Diagnosis Evaluation and Treatment Of Hepatitis C in CKD.http:\/\/kdigo.org\/guidelines\/hepatitis-c-in-ckd\/. Accessed December 11 2017."}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.13674","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.13674","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T16:26:43Z","timestamp":1694276803000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.13674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,31]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1111\/liv.13674"],"URL":"https:\/\/doi.org\/10.1111\/liv.13674","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"type":"print","value":"1478-3223"},{"type":"electronic","value":"1478-3231"}],"subject":[],"published":{"date-parts":[[2018,3,31]]},"assertion":[{"value":"2017-11-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}